2024
- 2023. 10.Recipeint of KDDF
(HER3 ADC Lead compound) - 2023. 09.KR patent registration of PMTTM Linker
- 2023. 08.Pre-IPO funding
2023
- 2023. 12.RCA with Samsung BioEpis
Patent application of NexatecanTM - 2023. 11.Winner of the Amgen-KHIDI Pitching day
- 2023. 10.AU patent registration of PMTTM Linker
- 2023. 09.US patent registration of PMTTM Linker
- 2023. 06.IN patent registration of PMTTM Linker
- 2023. 05.TW patent registration of PMTTM Linker
- 2023. 04.RU patent registration of PMTTM Linker
- 2023. 02.Application of NexatecanTM trademark
- 2023. 01.Application of OHPASTM trademark
2022
- 2022. 12.MTA with Option agreement with ADCT
- 2022. 11.JP patent registration of PMTTM Linker
- 2022. 07.Selected as a promising global unicorn venture company by the city of Daejeon
- 2022. 03.Recipeint of KDDF
(H3-H3 ADC Preclinical study)
2021
- 2021. 12.Patent application of PMTTM Linker
- 2021. 11.Recipeint of KDDF
(DLL3 ADC Lead compound) - 2021. 08.Certificate of INNOBIZ
- 2021. 03.Winner of the 2021 Korea Innovation Award for Technology Innovation
2020
- 2020. 11.Series C funding ($31M)
- 2020. 04.Split of stock
- 2020. 03.Increase of capital stock without consideration (bonus issue)
2019
- 2019. 12.Additional Series B’ funding
- 2019. 09.Registration of OHPASTM trademark
- 2020. 02.Recipient of KDDF funded by MSIT, MOTIE, and MOHW
2018
- 2018. 07.Relocation to Current Headquarters
- 2018. 03.Series B funding
2017
- 2017. 08.Initiation of B7-H3 ADC program
- 2017. 07.Patent application on OHPASTM Linker
2016
- 2016. 09.Series A' funding
- 2016. 01.Series A funding
2015
- 2015. 06.New R&D center in Daejeon
- 2015. 04.Seed funding from angel investors
- 2015. 04.Certificate of venture company
- 2015. 04.Founding of IntoCell